AgomAb Therapeutics

TLDR

AgomAb Therapeutics is a Ghent-based biotech developing antibody treatments for fibrosis, spun out of argenx, having raised $100M in a Series C round in 2023.

Overview

AgomAb Therapeutics was spun out of argenx, Ghent's globally recognized antibody platform company. AgomAb focuses on fibrosis, a condition where scar tissue builds up in organs and progressively impairs their function. There are limited treatment options for fibrosis across its multiple organ manifestations, making it a high-value target for drug development.

The $100M Series C in 2023 is a significant raise that positions AgomAb to advance its pipeline through clinical stages. The argenx lineage provides both scientific credibility and a network of relationships with global pharma partners.

AgomAb is part of the Ghent life sciences cluster, which includes argenx and a growing number of biotech spin-offs benefiting from proximity to Ghent University research.

Funding History

• Series C: $100M (2023)
• IPO on Nasdaq: $200M raised (February 2026), $16/share, valuation approximately $780M, ticker AGMB. Underwriters: JP Morgan, Morgan Stanley. See AgomAb Therapeutics IPO 2026.